The placebo response: relationship to outcomes in trials of postherpetic neuralgia.
Placebo responses in controlled studies of neuropathic pain, including postherpetic neuralgia, have increased in recent years and may obscure benefits of potential treatments. Investigations of the basis of the placebo effect have revealed some of the anatomical and physiological substrates for these responses. Placebo responses are accompanied by changes in activity in brain regions involved in analgesia, pain processing, reward and emotion, and they involve neurotransmitters with well established roles in pain modulation, including opioids and cholecystokinin. These findings may eventually provide useful suggestions for limiting placebo responses in clinical trials as identification of the cues that contribute to placebo responses could conceivably permit their avoidance in the design of clinical studies. Analyses of the characteristics of clinical trials in neuropathic pain have revealed some factors that might also help explain the increase in placebo responses. These factors include the longer duration of contemporary trials and recruitment practices of high-enrolling study centres. In trials of patients with postherpetic neuralgia, inclusion of patients with a short duration of post-zoster pain can result in a high rate of spontaneous remission that can contribute to an apparent 'placebo response'. Future placebo-controlled trials of treatments for postherpetic neuralgia may need to consider modifications of the design and conduct of these studies to maximize the chance of obtaining valid study results.
Irving
Gordon
G
Swedish Pain and Headache Center, Seattle, Washington 98104, USA. gordon.irving@swedish.org
D018849:Controlled Clinical Trials as Topic / Q000379:methods*; D006801:Humans; D051474:Neuralgia, Postherpetic / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D010147:Pain Measurement; D018579:Patient Selection; D015990:Placebo Effect; D012075:Remission, Spontaneous; D012107:Research Design; D013997:Time Factors; D016896:Treatment Outcome
Annu Rev Pharmacol Toxicol. 2008;48:33-60
17666008
Pain. 1991 Jul;46(1):43-51
1896207
QJM. 2005 Jan;98(1):29-34
15625351
Qual Inq. 2007 Sep;13(6):875-894
21359125
Anesthesiology. 2002 May;96(5):1053-61
11981142
Fundam Clin Pharmacol. 1995;9(5):409-33
8617406
Pain. 2009 Dec;146(3):261-269
19781854
N Engl J Med. 2005 Jun 2;352(22):2271-84
15930418
Clin J Pain. 2002 Sep-Oct;18(5):297-301
12218500
Neuron. 2007 Jul 19;55(2):325-36
17640532
J Opioid Manag. 2006 May-Jun;2(3):167-73
17319450
Neurology. 2005 Dec 29;65(12 Suppl 4):S7-19
16385107
Pain. 2001 Nov;94(2):215-224
11690735
J Pain. 2009 Jun;10(6):654-60
19409858
Pain. 2008 Jun;136(3):419-431
18400400
Annu Rev Psychol. 2008;59:565-90
17550344
Pain. 2002 Oct;99(3):443-452
12406519
Pain. 2005 Jun;115(3):338-347
15911161
Clin J Pain. 2000 Sep;16(3):188-92
11014390
J Pain Symptom Manage. 1999 Jun;17(6):429-33
10388248
Pain. 2010 Mar;148(3):368-374
19875233
Pain. 2007 Apr;128(3):264-271
17257756
J Pain. 2008 Nov;9(11):1006-17
18640074
Pain. 2009 Sep;145(1-2):36-44
19559529
Clin Ther. 1993 May-Jun;15(3):510-26
8364943
Neurology. 2008 Jan 22;70(4):263-72
17914067
Pain. 2008 Apr;135(3):217-220
18258369
Neurology. 2003 Apr 22;60(8):1274-83
12707429
J Infect Dis. 1998 Nov;178 Suppl 1:S71-5
9852979
Clin Pharmacol Ther. 1990 Mar;47(3):305-12
2178851
JAMA. 1998 Dec 2;280(21):1837-42
9846778
Neurology. 1988 Sep;38(9):1427-32
3412591
Science. 2004 Feb 20;303(5661):1162-7
14976306
Neuron. 2008 Jul 31;59(2):195-206
18667148
Curr Med Res Opin. 2006 Feb;22(2):375-84
16466610
J Pain Symptom Manage. 1999 Mar;17(3):175-80
10098360
Br J Clin Pharmacol. 2008 Aug;66(2):266-75
18489611
Spine (Phila Pa 1976). 1996 Feb 1;21(3):345-55
8742212
Science. 2002 Mar 1;295(5560):1737-40
11834781
Br J Anaesth. 2002 Nov;89(5):711-4
12393768
Pain. 2009 Sep;145(1-2):24-30
19523766
Lancet Neurol. 2008 Dec;7(12):1106-12
18977178
Pain. 1996 Apr;65(1):45-51
8826489
Pain. 2003 Jul;104(1-2):323-31
12855342
Clin J Pain. 2009 Mar-Apr;25(3):185-92
19333167
Pain. 2009 Nov;146(1-2):194-8
19692178
J Neurosci. 2006 Nov 15;26(46):12014-22
17108175
Pain. 2008 Jun;136(3):232-234
18384959
Pain. 2000 Jan;84(1):65-75
10601674
Pain. 2008 Sep 15;138(3):479-483
18706762
Clin Drug Investig. 2010;30(11):765-76
20818838
Neuron. 2005 Jun 16;46(6):957-69
15953423
Clin J Pain. 2009 Jul-Aug;25(6):469-76
19542793
N Engl J Med. 1996 Jul 4;335(1):32-42
8637540
Aging Clin Exp Res. 2009 Jun;21(3):236-43
19571648
Pain. 2007 Jan;127(1-2):63-72
16963184
Neurology. 1991 Jul;41(7):1024-8
1712433
Prog Neuropsychopharmacol Biol Psychiatry. 2005 Dec;29(8):1225-38
16242828
Clin J Pain. 2002 Nov-Dec;18(6):343-9
12441827
Neurology. 2002 Oct 8;59(7):1015-21
12370455
Clin J Pain. 2009 Jun;25(5):365-75
19454869